Saeed Sadeghi, MD
Hematology & Oncology · Santa Monica, CANPI 1144240334
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $550,110 of the $696,069 with a category attached, or 79.0%. 39 manufacturers reported payments, led by Lilly USA, LLC at 31.8% of the total. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 867 payments — averaging $802.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$221K
- E.r. Squibb & Sons, L.L.C.$95K
- Eisai Inc.$91K
- Johnson & Johnson$91K
- Pharmacyclics LLC, An Abbvie Company$41K
- Pfizer$36K
- plus $121K from 33 others
Across 135 payments — averaging $10,838 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$360K
- Genentech, Inc.$281K
- Jazz Pharmaceuticals Inc.$211K
- Boehringer Ingelheim$192K
- Hoffmann-la Roche Limited$125K
- Novartis$100K
- plus $195K from 5 others
What the payments were for
- Consulting fees$43,7256%
- Speaking & faculty fees$550,11079%
- Travel & lodging$85,46612%
- Food & beverage$16,1902%
- Education$5790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 275 | $221,357 |
| E.r. Squibb & Sons, L.L.C. | 51 | $95,172 |
| Eisai Inc. | 113 | $90,929 |
| Johnson & Johnson | 77 | $90,845 |
| Pharmacyclics LLC, An Abbvie Company | 39 | $41,330 |
| Pfizer | 53 | $35,810 |
| Seagen Inc. | 18 | $23,502 |
| AstraZeneca | 40 | $19,979 |
| Tesaro, Inc. | 13 | $14,345 |
| Exelixis Inc. | 20 | $14,252 |
| GSK | 13 | $10,936 |
| Bristol Myers Squibb | 17 | $8,865 |
| Helsinn Therapeutics (U.S.), Inc. | 5 | $7,012 |
| Eli Lilly | 20 | $6,875 |
| Dova Pharmaceuticals | 5 | $5,099 |
| Genentech USA, Inc. | 15 | $2,613 |
| Taiho Oncology, Inc. | 2 | $1,742 |
| Acceleron Pharma, Inc. | 1 | $845 |
| Array Biopharma Inc | 6 | $788 |
| Incyte Corporation | 5 | $763 |
| Bayer | 22 | $456 |
| Beigene, Ltd. | 1 | $450 |
| Athenex Pharmaceutical Division, LLC | 2 | $350 |
| Amgen | 12 | $314 |
| Mirati Therapeutics, Inc. | 2 | $253 |
| AbbVie | 7 | $193 |
| Regeneron Healthcare Solutions, Inc. | 1 | $141 |
| Stemline Therapeutics Inc. | 5 | $124 |
| Puma Biotechnology, Inc. | 5 | $111 |
| Clovis Oncology, Inc. | 1 | $99 |
| Novartis | 4 | $90 |
| Gilead | 4 | $87 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Sanofi | 2 | $59 |
| AVEO Pharmaceuticals, Inc. | 1 | $58 |
| Merck | 2 | $54 |
| Beigene USA, Inc. | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Sobi, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$696,069 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 59 | $849,605 |
| RevlimidLenalidomide | 18 | $414,782 |
| JakafiRuxolitinib Phosphate | 20 | $316,539 |
| PromactaEltrombopag Olamine | 23 | $288,910 |
| BrukinsaZanubrutinib | 24 | $286,277 |
| VenclextaVenetoclax | 20 | $280,628 |
| Lenalidomide | 18 | $252,009 |
| TagrissoOsimertinib Mesylate | 12 | $211,569 |
| VerzenioAbemaciclib | 15 | $204,372 |
| DopteletAvatrombopag Maleate | 15 | $174,023 |
| EliquisApixaban | 185 | $148,571 |
| XareltoRivaroxaban | 21 | $21,030 |
| Imatinib Mesylate | 19 | $4,881 |
| Hydroxyurea | 56 | $1,506 |
| Anastrozole | 77 | $1,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $41,330 | $849,60559 claims |
| Bristol Myers SquibbRevlimid | $8,865 | $414,78218 claims |
| Incyte CorporationJakafi | $763 | $316,53920 claims |
| NovartisPromacta | $90 | $288,91023 claims |
| Beigene USA, Inc.Brukinsa | $52 | $286,27724 claims |
| AbbVieVenclexta | $193 | $280,62820 claims |
| AstraZenecaTagrisso | $19,979 | $211,56912 claims |
| Lilly USA, LLCVerzenio | $221,357 | $204,37215 claims |
| Dova PharmaceuticalsDoptelet | $5,099 | $174,02315 claims |
| PfizerEliquis | $35,810 | $148,571185 claims |
| Johnson & JohnsonXarelto | $90,845 | $21,03021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Santa Monica
- Omid HamidSanta Monica$809K
- Richard FinnSanta Monica$784K
- Zev WainbergSanta Monica$761K
- Aditya BardiaSanta Monica$593K
- Steven OdaySanta Monica$270K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.